2-[[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl-2,2,4,4-d4]amino]-ethanesulfonicacid,monosodiumsalt

Taurocholic acid-d₄ (TCA-d₄) is intended for use as an internal standard for the quantification of TCA by GC- or LC-MS. TCA is a taurine-conjugated form of the primary bile acid cholic acid . Serum levels of TCA are decreased in patients with Crohn’s disease and those with ulcerative colitis with no extraintestinal manifestations, but are increased in patients with ulcerative colitis accompanied by hepatobiliary disease.

Taurocholic acid-d4 (sodium) is the deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats.

[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015 Oct;5(5):511-22. DOI:10.1007/s13346-015-0248-9